TickerFacts.

Amylyx Pharmaceuticals, Inc. (AMLX): Cost of Revenue

Annual figures by period end, from SEC filings.

$0
Year ended 2025-12-31
$25.44M2022-12-31: $2.99M2023-12-31: $25.44M2024-12-31: $5.95M2025-12-31: $0$0
2022-12-31 Cost of Revenue (USD) 2025-12-31
Period endedCost of RevenueChange YoYSource filing
2025-12-31$0-100.0%2026-03-03, From 2025-01-01
2024-12-31$5.95M-76.6%2026-03-03, From 2024-01-01
2023-12-31$25.44M+750.0%2025-03-04, From 2023-01-01
2022-12-31$2.99Mn/a2024-02-22, From 2022-01-01

Cost of Revenue at similar companies

Companies with the same SEC industry code (Pharmaceutical Preparations), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedCost of RevenueChange YoY
Amylyx Pharmaceuticals, Inc. (AMLX)2025-12-31$0-100.0%
Abbott Laboratories (ABT)2025-12-31$19.32B+3.3%
Bristol Myers Squibb Co (BMY)2025-12-31$13.94B-0.2%
Eli Lilly & Co (LLY)2025-12-31$11.05B+31.3%
Pfizer Inc (PFE)2025-12-31$16.07B-10.0%
Johnson & Johnson (JNJ)2025-12-28$30.26B+10.1%
Nature's Sunshine Products Inc (NATR)2025-12-31$132.42M+2.1%
Merck & Co., Inc. (MRK)2025-12-31$16.38B+7.8%
Heron Therapeutics, Inc. (HRTX)2025-12-31$41.35M+7.0%

Compare AMLX, ABT, BMY, LLY side by side · Screen every company in Pharmaceutical Preparations ↗